Cowen analyst Joshua Jennings downgraded Apollo Endosurgery (APEN) to Market Perform from Outperform with a price target of $10, down from $13, after Boston Scientific (BSX) announced a deal to acquire the company for $10 per share in cash back in November.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on APEN:
- Apollo Endosurgery downgraded to Hold from Buy at Stifel
- Apollo Endosurgery announces two milestones for endoscopic systems
- Apollo Endosurgery advances endoscopic procedures for obese patients
- SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – VVNT, SAL, GRAY, APEN
- Apollo Endosurgery downgraded to Hold from Buy at Lake Street